Singapore-based biopharmaceutical company Axcynsis Therapeutics Pte Ltd announced on Wednesday that its Investigational New Drug application (IND) for AT03-65 has received clearance from the US Food and Drug Administration (FDA) for the treatment of patients with CLDN-6 positive solid tumours.
The company is planning to commence a Phase 1 multicentre clinical trial in the United States in the first quarter of 2025.
AT03-65 is a differentiated Antibody Drug Conjugate (ADC) that selectively binds to CLDN6 with strong affinity. It is enabled by AxcynDOT, a proprietary payload that incorporates a derivative of an approved oncology therapeutics with unique mechanism of action and broad anti-tumour activity, and coupled with a cleavable and hydrophilic proprietary linker. AT03-65 is designed to target advanced, recurrent, or metastatic CLDN6+ solid tumours in patients who have progressed on or after standard systemic treatment or for whom no standard therapies are available.
The Phase 1 trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AT03-65 in patients with advanced CLDN6-positive solid tumours.
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma